SCHEMBL4605977

SCHEMBL4605977

CCC(=O)Nc1ccc(/C=C/c2ccccc2OC(F)(F)F)cc1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 6/20 0.41
HSD17B10 Q99714 3/20 0.41
IGF2BP2 Q9Y6M1 1/20 0.41
TRPA1 O75762 2/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
GAA P10253 1/20 0.40
APP P05067 2/20 0.39
F2R P25116 1/20 0.39
RORC P51449 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
TP53 P04637 2/20 0.39
CYP3A4 P08684 2/20 0.39
HPGD P15428 2/20 0.39
HIF1A Q16665 2/20 0.39
MAPK1 P28482 2/20 0.39
PKM P14618 2/20 0.39
SNCA P37840 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4605979 1.00 KDM4E (0.41) KDM4EALDH1A1HSD17B10IGF2BP2TRPA1
SCHEMBL1823874 0.84 KDM4E (0.44) KDM4EALDH1A1IGF2BP2GAAAPP
SCHEMBL1826002 0.84 KDM4E (0.44) KDM4EALDH1A1IGF2BP2GAAAPP
SCHEMBL4605442 0.84 BACE1 (0.46) KDM4EALDH1A1TRPA1TRPM8APP
SCHEMBL4605447 0.84 BACE1 (0.46) KDM4EALDH1A1TRPA1TRPM8APP
SCHEMBL4605307 0.83 IGF2BP2 (0.47) KDM4EALDH1A1IGF2BP2MEN1KMT2A
SCHEMBL4605305 0.83 IGF2BP2 (0.47) KDM4EALDH1A1IGF2BP2MEN1KMT2A
SCHEMBL4606313 0.83 KCNA3 (0.46) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL4606305 0.83 KCNA3 (0.46) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL4604659 0.81 ADORA3 (0.54) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1914152-B New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB 2010-06-09 CN disclosed
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
CN-1914152-A New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2007-02-14 CN disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 KDM4E 2898/4885ALDH1A1 308/4885HSD17B10 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.